The liposomal delivery of chemotherapy is a promising therapeutic area, which was highlighted by the approval of CPX-351 for two types of typically hard-to-treat secondary acute myeloid leukemia (AML). In this interview, Jeffrey Lancet, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the diverse next steps in this field. Dr Lancet covers identifying responders, investigating the drugs effect on transplant success and potential combinations with targeted therapy. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.
What are the next steps for liposomal chemotherapy delivery and CPX-351?
